Eosinophilia Myalgia Syndrome is associated with the ingestion of large amounts of contaminated L-tryptophan, a dietary supplement often sold in health food stores. The contaminant remains unknown. It is a disease of abrupt onset causing severe, disabling, chronic muscle pain, skin symptoms and other neurotoxic reactions . Diagnosis is not easy and depends on finding unusually high levels of eosinophils (circulating white blood cells) over a period of at least six months.
Eosinophilia Myalgia Syndrome may make its presense known only weeks, months, or even years after the original period of high-volume consumption of L-tryptophan. L-tryptophan is an essential amino acid present in most foods. However, when it is purchased as a "health food", people often take doses much higher than would be present in the normal diet. The disorder is characterized by large amounts of eosinophils (white blood cells) in the blood. The primary symptom is severe muscle pain and weakness. There may also be associated ulcers of the mouth or other mucous membranes. Sore throat, difficulty breathing (dyspnea), swollen liver and abdomen, abdominal pain, and fever may also be present.
Skin abnormalities resembling Scleroderma, including swelling and tightening of the skin, painful itching, and edema, along with peau d'orange skin of the legs, may also occur. The skin symptoms usually start in the extremities (usually the legs) with the upper body becoming involved later if at all.
Eosinophilia Myalgia may be caused by the ingestion of some lots of oral L-tryptophan. Tryptophan is an essential amino acid present in very small quantities in most foods. However, the amounts ingested by patients with Eosinophilia Myalgia are over and above the amounts occuring naturally in food. The drug was formerly available at health food stores without prescription as a dietary supplement. Although there was no proof of effectiveness, many patients used it to treat depression, premenstrual syndrome and insomnia. During 1990 the FDA removed tryptophan from the shelves of stores and it can no longer be purchased in this country. Scientists are still trying to determine whether the tryptophan itself causes predisposed persons to manufacture neurotoxins that cause Eosinophilia Myalgia symptoms, or whether the tryptophan is in some way contaminated in the manufacturing process.
Scientists now believe they can confirm that L-tryptophan itself causes symptoms of EMS in patients who use the product. Further studies have shown that L-tryptophan contaminated with 1-1-ethylidenebis (ETB) causes more severe problems in people than regular L-tryptophan; still, L-tryptophan alone can cause EMS.
Eosinophilia Myalgia seems to affect males and females in equal numbers. The Centers of Disease Control states that as of February, 1990, 1269 cases were reported to them. Some patients have died.
Symptoms of the following disorders can be similar to those of Eosinophilia Myalgia. Comparisons may be useful for a differential diagnosis:
Scleroderma refers to a group of chronic disorders characterized by fibrosis, degenerative changes, and vascular abnormalities in the skin. Scleroderma is the chronic hardening and shrinking of the connective tissues of any part of the body, although the term literally means "hardening of the skin." (For more information on this disorder, choose "Scleroderma" as your search term in the Rare Disease Database.)
Trichinosis is a disorder that is caused by the parasitic round worm Trichinella spiralis. Persons become infected by eating raw or undercooked pork that contains cysts of the parasite. The symptoms include swelling of the eyelids, and mucous membranes. Aching of the muscles, fever, and increasing weakness may also be present.
Toxic Oil Syndrome was an epidemic disorder associated with the eating of contaminated cooking oil that swept Spain during the summer of 1981 and affected over 20,000 persons. Its features were an initial phase of fever and pneumonitis, then gastrointestinal dysfunction and severe eosinophilia, severe myalgia, muscle contractures and severe muscular pain.
Eosinophilic Fasciitis commonly occurs in the fourth to sixth decades of life. The initial symptoms may include pain, swelling and inflammation of the skin, which usually takes on a characteristic orange-peel appearance. The arms and forearms are affected more often than the thighs and legs. Arm and leg movements gradually become restricted. Inflammation of the tendons often leads to contractures of the fingers and Carpal Tunnel Syndrome. Onset of Eosinophilic Fasciitis has, in some cases, been related to the ingestion of the dietary supplement tryptophan. Symptoms most commonly follow strenuous physical activity. (For more information on this disorder, choose "Eosinophilic Fasciitis" as your search term in the Rare Disease Database.)
Treatment of Eosinophilic Myalgia consists of high doses of glucocorticoids (Hydrocortisone) to reduce the amount of circulating eosinophils. This treatment, however, does not usually improve the other symptoms.
Research on Eosinophilic Myalgia is ongoing. For more information about investigational therapies contact the Centers for Disease Control listed below.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Puszczewicz M, Zimmermann-Górska I, Pietrzak-Kaczmarek H, Lazowski S. Diagnostic problems in eosinophilic fasciitis. Pol Arch Med Wewn. 2006 Aug;116(2):777-80.
Solomon J, Schwarz M. Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia. Semin Respir Crit Care Med. 2006 Apr;27(2):192-7.
EOSINOPHILIC MYOPATHIC SYNDROMES. M. C. Pickering et al., Current Opin Rheumatol. (Nov 1998, 10 (6)). Pp. 504-10.
NEUROLOGIC, MR IMAGING AND MR SPECTROSCOPIC FINDINGS IN EOSINOPHILIA MYALGIA SYNDROME. L. J. Haseler et al., AJNR Am J Neuroradiol. (Oct 1998, 19 (9)). Pp. 1687-94.
PAIN, FATIGUE, AND SLEEP IN EOSINOPHILIA-MYALGIA SYNDROME: RELATIONSHIP TO NEUROPSYCHOLOGICAL PERFORMANCE. D. A. Pollina et al., J Neuropsychiatry Clin Neurosci. (Summer 1998, 10 (3)). Pp. 338-42.
STRUCTURAL CHARACTERIZATION OF CONTAMINANTS FOUND IN COMMERCIAL PREPARATIONS OF MELATONIN: SIMILARITIES TO CASE-RELATED COMPOUNDS FROM L-TRYPTOPHAN ASSOCIATED WITH EOSINOPHILIA-MYALGIA SYNDROME. B. L. Williamson et al., Chem Res Toxicol. (Mar 1998, 11 (3)). Pp. 234-40.
ASSOCIATION OF THE EOSINOPHILIA-MYALGIA SYNDROME WITH THE INGESTION OF TRYPTOPHAN. P. A. Hertzman et al.; New Eng J Med (Mar 29 1990; 322(13)). Pp. 869-73.
SCLERODERMA, FASCIITIS, AND EOSINOPHILIA ASSOCIATED WITH THE INGESTION OF TRYPTOPHAN. R. M. Silver et al.; New Eng J Med (Mar 29 1990; 322(13)). Pp. 874-81.
TRYPTOPHAN-INDUCED EOSINOPHILIA-MYALGIA SYNDROME. T. A. Medsger Jr.; New Eng J Med (Mar 29 1990; 322(13)). Pp. 926-28.
Centers for Disease Control and Prevention 1600 Clifton Road NE Atlanta, GA 30333 Tel: (404)639-3534 Tel: (800)311-3435 Email: http://www.cdc.gov/netinfo.htm Internet: http://www.cdc.gov/
NIH/National Arthritis and Musculoskeletal and Skin Diseases Information Clearinghouse 1 AMS Circle Bethesda, MD 20892-3675 USA Tel: (301)495-4484 Fax: (301)718-6366 Tel: (877)226-4267 TDD: (301)565-2966 Email: NIAMSinfo@mail.nih.gov Internet: http://www.niams.nih.gov/Health_Info
National Eosinophilia Myalgia Syndrome Network Jann Heston, President PO Box 3016 155 Delaware Avenue Lexington, OH 44904-1212 USA Tel: (614)583-5720 Fax: (614)737-7384 Email: NEMSN2005@aol.com Internet: http://www.NEMSN.org
Genetic and Rare Diseases (GARD) Information Center PO Box 8126 Gaithersburg, MD 20898-8126 Tel: (301)519-3194 Fax: (240)632-9164 Tel: (888)205-2311 TDD: (888)205-3223 Email: gardinfo@nih.gov Internet: http://www.genome.gov/10000409
Madisons Foundation PO Box 241956 Los Angeles, CA 90024 Tel: (310)264-0826 Fax: (310)264-4766 Email: getinfo@madisonsfoundation.org Internet: http://www.madisonsfoundation.org
Campaign Urging Research for Eosinophilic Disease (CURED) 2937 Bayberry Dr. Buffalo Grove, IL 60089 Tel: (847)793-0071 Email: ellyn@curedfoundation.org Internet: http://www.curedfoundation.org
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). CIGNA members can access the complete report by logging into myCIGNA.com. For non-CIGNA members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email orphan@rarediseases.org
Last Updated: 4/25/2008 Copyright 1990, 1991, 1992, 1999 National Organization for Rare Disorders, Inc.
This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.